SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|
| RELENZA 5MG POWDER FOR INHALATION | 5 mg | Inhalation powder · Inhalation use | 1 Multidose container | SAR 60.95 | NCE · Prescription | Glaxo Saudi Arabia Ltd | Valid |
Indications — CHI Daman Drug Formulary
SICKLE CELL DISEASE - INFLUENZA; TRAVEL RELATED INFECTIONS-INFLUENZA PROPHYLAXIS; TRAVEL RELATED INFECTIONS-TREATMENT
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|
| RELENZA | 5MG | powder · inhalation | GLAXOSMITHKLINE | Prescription | 26 Jul 1999 |
EMA European Union — centrally authorised medicines
Dectova GlaxoSmithKline Trading Services Limited · Authorised · authorised 26 Apr 2019 · ATC J05AH01
Therapeutic indication (EMA)
Dectova is indicated for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ?6 months) when: The patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or Other anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient. Dectova should be used in accordance with official guidance.
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|
| RELENZA | 02240863 | 5 MG / ACT | POWDER · INHALATION; ORAL | GLAXOSMITHKLINE INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|
| NHS Drug Tariff | Zanamivir 5mg inhalation powder blisters with device | £16.36 | 20 blister | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.